MicroRNAs-mediated epithelial-mesenchymal transition in fibrotic diseases

详细信息    查看全文

• 作者：Xiao-Zhou Zou^a ; Ting Liu^a ; Zhi-Cheng Gong^c ; Chang-Ping Hu^a ; ^b ; ^{huchangping@yahoo.com} ; Zheng Zhang^a ; ^b ; ^{zzhang@csu.edu.cn}
• 关键词：MicroRNAs ; Epithelial-mesenchymal transition ; Fibrotic diseases
• 刊名：European Journal of Pharmacology
• 出版年：2017
• 出版时间：5 February 2017
• 年：2017
• 卷：796
• 期：Complete
• 页码：190-206
• 全文大小：685 K
• 卷排序：796

文摘

MicroRNAs (miRNAs), a large family of small and highly conserved non-coding RNAs, regulate gene expression through translational repression or mRNA degradation. Aberrant expression of miRNAs underlies a spectrum of diseases including organ fibrosis. Recent evidence suggests that miRNAs contribute to organ fibrosis through mediating epithelial-mesenchymal transition (EMT). Alleviation of EMT has been proposed as a promising strategy against fibrotic diseases given the key role of EMT in fibrosis. miRNAs impact the expression of specific ligands, receptors, and signaling pathways, thus modulating EMT and consequently influencing fibrosis. This review summarizes the current knowledge concerning how miRNAs regulate EMT and highlights the specific roles that miRNAs-regulated EMT plays in fibrotic diseases as diverse as pulmonary fibrosis, hepatic fibrosis, renal fibrosis and cardiac fibrosis. It is desirable that a more comprehensive understanding of the functions of miRNAs-regulated EMT will facilitate the development of novel diagnostic and therapeutic strategies for various debilitating organ fibrosis.